MannKind (MNKD) Competitors $6.85 +0.55 (+8.73%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends MNKD vs. MDGL, HALO, IONS, ALKS, FOLD, LGND, GERN, CLDX, DVAX, and BCRXShould you be buying MannKind stock or one of its competitors? The main competitors of MannKind include Madrigal Pharmaceuticals (MDGL), Halozyme Therapeutics (HALO), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Amicus Therapeutics (FOLD), Ligand Pharmaceuticals (LGND), Geron (GERN), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), and BioCryst Pharmaceuticals (BCRX). These companies are all part of the "biotechnology" industry. MannKind vs. Madrigal Pharmaceuticals Halozyme Therapeutics Ionis Pharmaceuticals Alkermes Amicus Therapeutics Ligand Pharmaceuticals Geron Celldex Therapeutics Dynavax Technologies BioCryst Pharmaceuticals Madrigal Pharmaceuticals (NASDAQ:MDGL) and MannKind (NASDAQ:MNKD) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, community ranking, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment. Does the MarketBeat Community prefer MDGL or MNKD? MannKind received 125 more outperform votes than Madrigal Pharmaceuticals when rated by MarketBeat users. However, 67.70% of users gave Madrigal Pharmaceuticals an outperform vote while only 60.12% of users gave MannKind an outperform vote. CompanyUnderperformOutperformMadrigal PharmaceuticalsOutperform Votes45767.70% Underperform Votes21832.30% MannKindOutperform Votes58260.12% Underperform Votes38639.88% Which has stronger valuation and earnings, MDGL or MNKD? MannKind has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than MannKind, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMadrigal Pharmaceuticals$76.81M87.58-$373.63M-$25.08-12.30MannKind$267.20M7.07-$11.94M$0.0797.86 Do insiders & institutionals have more ownership in MDGL or MNKD? 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. Comparatively, 49.5% of MannKind shares are held by institutional investors. 22.8% of Madrigal Pharmaceuticals shares are held by insiders. Comparatively, 3.0% of MannKind shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is MDGL or MNKD more profitable? MannKind has a net margin of 8.07% compared to Madrigal Pharmaceuticals' net margin of 0.00%. MannKind's return on equity of -17.74% beat Madrigal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Madrigal PharmaceuticalsN/A -71.78% -53.25% MannKind 8.07%-17.74%8.68% Which has more risk and volatility, MDGL or MNKD? Madrigal Pharmaceuticals has a beta of -0.42, suggesting that its share price is 142% less volatile than the S&P 500. Comparatively, MannKind has a beta of 1.28, suggesting that its share price is 28% more volatile than the S&P 500. Does the media prefer MDGL or MNKD? In the previous week, MannKind had 22 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 29 mentions for MannKind and 7 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 1.28 beat MannKind's score of 0.54 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Madrigal Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MannKind 7 Very Positive mention(s) 3 Positive mention(s) 13 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend MDGL or MNKD? Madrigal Pharmaceuticals currently has a consensus target price of $347.33, indicating a potential upside of 12.61%. MannKind has a consensus target price of $8.88, indicating a potential upside of 29.56%. Given MannKind's stronger consensus rating and higher possible upside, analysts plainly believe MannKind is more favorable than Madrigal Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Madrigal Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.69MannKind 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 SummaryMannKind beats Madrigal Pharmaceuticals on 13 of the 19 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get MannKind News Delivered to You Automatically Sign up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MNKD vs. The Competition Export to ExcelMetricMannKindPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.89B$6.58B$5.01B$9.08BDividend YieldN/A3.09%4.87%4.18%P/E Ratio97.8610.55135.4317.18Price / Sales7.07194.011,119.53115.67Price / CashN/A57.1640.5837.88Price / Book-7.535.104.754.78Net Income-$11.94M$151.51M$118.50M$225.60M7 Day Performance4.74%-2.16%-1.83%-1.26%1 Month Performance-0.44%-2.91%12.27%4.37%1 Year Performance105.40%13.93%31.72%18.73% MannKind Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MNKDMannKind3.199 of 5 stars$6.85+8.7%$8.88+29.6%+105.4%$1.80B$198.96M97.86400Analyst UpgradeAnalyst RevisionNews CoverageHigh Trading VolumeMDGLMadrigal Pharmaceuticals4.2369 of 5 stars$310.87+2.1%$347.33+11.7%+39.5%$6.78BN/A-12.1490Positive NewsHALOHalozyme Therapeutics4.9948 of 5 stars$48.39+0.8%$61.11+26.3%+29.1%$6.16B$947.36M15.98390Analyst ForecastPositive NewsIONSIonis Pharmaceuticals4.409 of 5 stars$38.46+5.1%$60.65+57.7%-26.3%$6.07B$803.07M-15.00800Analyst ForecastShort Interest ↓Analyst RevisionNews CoveragePositive NewsALKSAlkermes4.6513 of 5 stars$30.76+0.8%$35.42+15.1%+9.3%$4.98B$1.51B15.652,100Positive NewsFOLDAmicus Therapeutics4.326 of 5 stars$9.90+5.8%$16.88+70.5%-23.7%$2.96B$493.67M-28.71480Analyst DowngradeLGNDLigand Pharmaceuticals4.9816 of 5 stars$123.60+5.7%$147.00+18.9%+65.4%$2.34B$152.42M47.4480Analyst RevisionGERNGeron3.84 of 5 stars$3.79-1.8%$7.15+88.7%+61.6%$2.29B$29.48M-12.06141Short Interest ↓CLDXCelldex Therapeutics2.6773 of 5 stars$26.43+4.0%$62.25+135.5%-33.5%$1.75B$6.88M-9.89160Analyst ForecastNews CoveragePositive NewsDVAXDynavax Technologies4.767 of 5 stars$12.98+0.2%$22.00+69.5%-4.1%$1.71B$260.81M100.00408Positive NewsBCRXBioCryst Pharmaceuticals3.7226 of 5 stars$7.36-2.3%$15.60+112.0%+34.2%$1.52B$412.58M-12.34530Positive News Related Companies and Tools Related Companies Madrigal Pharmaceuticals Alternatives Halozyme Therapeutics Alternatives Ionis Pharmaceuticals Alternatives Alkermes Alternatives Amicus Therapeutics Alternatives Ligand Pharmaceuticals Alternatives Geron Alternatives Celldex Therapeutics Alternatives Dynavax Technologies Alternatives BioCryst Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MNKD) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredWhat most folks don’t know about oil (BIG missed opportunity)$1 Trillion… That’s how much Big Tech is set to spend on AI investment in the coming months—according to Go...ProsperityPub | SponsoredHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buyi...Insiders Exposed | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | Sponsored2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—wit...Darwin | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MannKind Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share MannKind With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MNKD Stock Alerts